Copeptin levels are more elevated and associated with cardiovascular events in the unity of chronic ischemic heart and chronic kidney diseases

Objective: Copeptin comprises the C-terminal part of the Arginine vasopressin (AVP) precursor, is co-secreted with AVP and is a stable surrogate marker for AVP release, making it much easier to measure. Elevated levels of serum copeptin in both cardiovascular and renal diseases were known but the amount and predictive value of copeptin in the unity of these diseases is unknown.Methods: A study composed equally divided five groups, total of 150 adult patients. Group I and group II composed study groups which included the patients of chronic ischemic heart (CHID) and chronic kidney diseases (CKD) respectively. Control groups such as group III, IV and V included only patients of CHID or CKD. Copeptin, hs-CRP and pro-BNP levels were analyzed in all patients and their relationship with adverse outcomes were evaluated.Results: Serum levels of copeptin, hs-CRP and pro-BNP were higher in patients of study groups than patients of control groups and it was found statistically meaningful (p

Kronik İskemik Kalp ve Kronik Böbrek Yetmezliği Hastalıklarının Birlikteliğinde Kopeptin Düzeyi Çok Daha Yüksek ve Kardiyovasküler Olaylarla İlişkilidir

Giriş: Kopeptin, Arjinin vasopressinin (AVP) C-terminal kısmını oluşturur ve oda sıcaklığında stabil olduğundan serumdaki düzeyini belirlemede kolaylık sağlar. Hem kardiyovasküler hem de böbrek hastalıklarında yüksek kopeptin düzeyinin olumsuz olayları ön görücülüğü bilinmekte ise de bu iki hastalığın birlikteliğinde kopeptin düzeyinin ne kadar yüksek olduğu ve olumsuz olayları ön görücülüğü bilinmemektedir. Yöntemler: Çalışmaya toplam 150 hasta dahil edilmiş olup 5 eşit gruba bölünmüşlerdir. Grup 1 kronik iskemik kalp hastalarını, grup 2 ise kronik böbrek hastalarını ihtiva etmektedir. Grup 3,4 ve 5 kontrol grubunu oluşturmaktadır. Tüm hastaların kopeptin, hs-CRP ve pro-BNP düzeyleri ölçülerek olumsuz sonuçlar ile ilişkileri değerlendirilmiştir. Bulgular: Çalışma grubu hastalarında kopeptin, pro-BNP ve hs-CRP düzeyleri kontrol grubuna göre istatistiksel olarak daha yüksek bulundu (p

PDF

___

1.Morgenthaler NG, Struck J, Alonso C, Bergmann A.Assay for the measurement of copeptin, a stablepeptide derived from the precursor of vasopressin.Clin Chem 2006; 52: 112-9.

2.Reichlin T, Hochholzer W, Stelzig C, et al.Incremental value of copeptin for rapid rule out ofacute myocardial infarction. J Am Coll Cardiol. 2009;54: 60-8.

3.Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminalprovasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: LeicesterAcute Myocardial Infarction Peptide (LAMP) study.Circulation 2007; 115: 2103–10.

4.Vachharajani TJ, Zaman F, Abreo KD.Hyponatremia in critically ill patients. J IntensiveCare Med. 2003; 18: 3–8.

5. Bardoux P, Bichet DG, Martin H, Gallois y, Marre m. Vasopressin increases urinary albumin excretion inrats and humans: involvement of V2 receptors andthe renin-angiotensin system. Nephrol DialTransplant. 2003; 18: 497–506.

6.Fernandes S, Bruneval P, Hagege A, et al. ChronicV2 vasopressin receptor stimulation increases basalblood pressure and exacerbatesdeoxycorticosterone acetate-salt hypertension.Endocrinology 2002; 143: 2759–66.

7.Szinnai G, Morgenthaler NG, Berneis K, et al.Changes in plasma copeptin, the C-terminal portionof arginine vasopressin during water deprivationand excess in healthy subjects. J Clin EndocrinolMetab. 2007; 92: 3973–8.

8.Morgenthaler NG, Müller B, Struck J, et al.Copeptin, a stable peptide of the argininevasopressin precursor, is elevated in hemorrhagicand septic shock. Shock 2007; 28: 644–9.

9.Chenevier-Gobeaux C, Freund Y, Claessens YE, etal. Copeptin for rapid rule out of acute myocardialinfarction in emergency department. Int J Cardiol2013; 166: 198-204.

10.Von Haehling S, Papassotiriou J, MorgenthalerNG, et al. Copeptin as a prognostic factor for majoradverse cardiovascular events in patients withcoronary artery disease. Int J Cardiol 2012; 162: 27-32.

11.Chai SB, Hui YM, Li XM, Xiao Y, Tang CS. Plasmalevels of copeptin in patientswith coronary heartdisease. Heart Vessels 2009; 24: 79-83.

12.Keller T, Blankenberg S. Copeptin improves earlydiagnosis of acute myocardial infarction. Circulation2009; 120: 1035.

13.Li X, Yang XC, Sun QM, Chen XD, Li YC. Brainnatriuretic peptide and copeptin levels areassociated with cardiovascular disease in patientswith chronic kidney disease. Chin Med J (Engl) 2013;126: 823-7.

14.Fenske W, Wanner C, Allolio B, et al. Copeptinlevels associate withcardiovascular events inpatients with ESRD and type 2 diabetes mellitus. JAm Soc Nephrol 2011; 22: 782-90.